Value Investors: 1 Cheap Cannabis Stock to Own

Organigram Holdings Inc. (TSX:OGI)(NASDAQ:OGI) has huge potential due to the company’s broad offering of medical cannabis products.

| More on:
Cannabis stocks have fallen.

Organigram Holdings (TSX:OGI)(NASDAQ:OGI) is a leading Canadian licensed producer of high-quality cannabis and cannabis-derived products in Canada. The company is focused on producing high-quality, indoor-grown cannabis primarily for adult recreational consumers in Canada and the medical market as well as developing international business partnerships to extend the company’s global footprint.

High-quality products and brands

The company has been working on establishing strong brands for use in the adult-use recreational market place and is seeking to create a portfolio of diverse brands and products. The company’s adult-use recreational brands strategy reflects Organigram’s views about current and potential consumers, the industry, future product development, and opportunities for growth.

Huge recreational cannabis opportunity

The company developed an initial portfolio of adult-use recreational brands to specifically meet the evolving needs of Canada’s recreational use market. The suite of brands created by the Company for Canada’s adult-use market include Edison Cannabis, Trail Blazer, and SHRED. Each brand is unique to a specific customer demographic with a product offering designed to meet the needs of the target audience, including as to strength and price point.

Medical cannabis

The company received a medical cannabis certification and now offers organically grown medical cannabis under the certification body. The company offers a broad offering of medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers to suit a variety of preferences.

New product development

The company plans to bring a variety of cannabis-based products to market. Such products are at various stages of development, including edible products, vape pens, chocolate, and dissolvable powdered beverages. These products require 60-day advance new product notifications to be submitted to Health Canada before they can be sold.

Efficient operations

The company has assembled a capable management team with significant experience in the management and growth of successful enterprises. Coupled with operational experience, the company is a cost-competitive producer of cannabis, owing to various operational cost-saving attributes such as competitive power costs and competitive labour costs.

Further, the company has a facility that maximizes real property square footage through the use of tiered grow rooms.

Other cost-saving attributes include competitive real property costs, the adoption of various efficiencies and access to various government assistance programs. Substantially all of the company’s revenue is derived from the sale of cannabis, cannabis product, and cannabis plant material produced, which is cultivated and processed by the company.

Capital markets risk

An economic downturn of global capital markets would make the raising of capital by equity or debt financing is difficult. The company is dependent upon the capital markets to raise additional financing in the future, while it establishes a user base.

As such, the company is subject to liquidity risks in meeting development and future operating cost requirements in instances where cash positions are unable to be maintained or appropriate financing is unavailable. These factors could impact the company’s ability to raise equity or obtain loans and other credit facilities in the future and on favourable terms.

Despite risks, Organigram has huge potential due to the company’s broad offering of medical cannabis products.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Here’s Why it’s Not Too Late to Buy Cronos Group Stock

The optimism about U.S. federal marijuana legalization and its anticipation are potent bullish triggers for the Canadian cannabis industry.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now? 

Canopy Growth (TSX:WEED) stock surged by 80% from news out of the U.S., but is enough there without the news…

Read more »